THE neurologic manifestations of Central-nervous-system involvement in acute leukemia have been very well described. 1–7 Although involvement of the brain is not rare 7,8 greater emphasis has been ...
In a recent study published in Nanomedicine: Nanotechnology, Biology and Medicine, researchers evaluated the biodistribution of cannabidiol (CBD) emulsion and nanoparticles in the central nervous ...
A novel indwelling subcutaneous intrathecal catheter circumvented the complex spine anatomy of patients with spinal muscular atrophy (SMA), a challenge when giving nusinersen via intrathecal injection ...
Credit: FDA. The FDA has received reports of tranexamic acid injection being erroneously administered intrathecally in the perioperative setting instead of the intended intrathecal anesthetic (eg, ...
Study design: Case series of a consecutive sample. Retrospective audit. Objective: To analyze the long-term safety and efficacy of intrathecal baclofen (ITB), and technical incidents. Setting: ...
Glycine, taurine, or muscimol was injected with bicuculline into the cistern magna or the lumbar subarachnoidal space in ICR mice. The effects on bicuculline-induced allodynia in a touch-evoked ...
Phase I study of vorinostat (suberoylanilide hydroxamic acid) in combination with temozolomide (TMZ) in patients with malignant gliomas (NABTC 04–03) No significant financial relationships to disclose ...
Panelists discuss how intrathecal delivery of onasemnogene abeparvovec in the STEER study demonstrates statistically significant motor function improvements in older patients with SMA (ages 2-18 years ...
September 14, 2012 — The US Food and Drug Administration (FDA) has approved a new catheter (Ascenda, Medtronic Inc) for use in the delivery of intrathecal baclofen (ITB) therapy. According to the ...
The following represents disclosure information provided by author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...
Novartis has reported phase 1/2 trial results with its intrathecal formulation of gene therapy Zolgensma, placed under a clinical hold by the FDA last year, backing up its safety and efficacy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results